BiotechTube
Home/Imugene/Christina Chong
CC

Christina Chong

Non-Executive Director

Imugene

Therapeutic Areas

OncologyImmuno-oncology

Imugene Pipeline

DrugIndicationPhase
HER-Vaxx (IMU-131)HER-2/neu positive gastric & gastroesophageal junction cancerPhase 2b
CHECKvacc (CF33-hNIS-antiPDL1)Advanced or metastatic solid tumorsPhase 1
VAXINIA (CF33-hNIS)Advanced or metastatic solid tumorsPhase 1
PD1-Vaxx (IMU-201)Non-small cell lung cancer (NSCLC)Phase 1
CD19 onCARlyticsB-cell hematological malignancies (e.g., Leukemia, Lymphoma)Pre-clinical
CD20 onCARlyticsB-cell hematological malignanciesPre-clinical
BA3071Solid tumorsPre-clinical

Leadership Team at Imugene

LC
Leslie Chong
Managing Director & Chief Executive Officer
PH
Paul Hopper
Executive Chairman
SL
Steven Lo
Non-Executive Director
DB
Dr. Bryan Dulski
Non-Executive Director
DS
Dr. Sanjay S. Joshi
Chief Technology Officer
View full Imugene profile